MOBILE VIEW  | 
Document View > MS alpha-fetoprotein level

MS alpha-fetoprotein level

MS alpha-fetoprotein level

MS alpha-fetoprotein level

Canick JA, Kellner LH, & Bombard AT: Prenatal screening for open neural tube defects. Clin Lab Med 2003; 23:385-394.

Benn PA, Clive JM, & Collins R: Medians for second-trimester maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol; differences between races or ethnic groups. Clin Chem 1997; 43(2):333-7.

Chan A, Robertson EF, Haan EA, et al: The sensitivity of ultrasound and serum alpha-fetoprotein in population-based antenatal screening for neural tube defects. South Australia 1986-1991. Br J Obstet Gynaecol 1995; 102(5):370-6.

Rose NC & Mennuti MT: Maternal serum screening for neural tube defects and fetal chromosome abnormalities. West J Med 1993; 159(3):312-317.

Bock JL: Current issues in maternal serum alpha-fetoprotein screening. Am J Clin Pathol 1992; 97(4):541-554.

Killam WP, Miller RC, & Seeds JW: Extremely high maternal serum alpha-fetoprotein levels at second-trimester screening. Obstet Gynecol 1991; 78(2):257-61.

Waller DK, Lustig LS, Cunningham GC, et al: Second-trimester maternal serum alpha-fetoprotein levels and the risk of subsequent fetal death. N Engl J Med 1991; 325(1):6-10.

Johnson AM, Palomaki GE, & Haddow JE: Maternal serum alpha-fetoprotein levels in pregnancies among black and white women with fetal open spina bifida: a United States collaborative study. Am J Obstet Gynecol 1990; 162(2):328-31.

Wald NJ, Cuckle H, Brock JH, et al: Maternal serum-alpha-fetoprotein measurement in antenatal screening for anencephaly and spina bifida in early pregnancy. Report of U.K. collaborative study on alpha-fetoprotein in relation to neural-tube defects. Lancet 1977; 1(8026):1323-32.